INKT - NASDAQ

MiNK Therapeutics, Inc.

INKT·NASDAQ

$12.76

+1.4%

HealthcareBiotechnology

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$63.57M

EPS-2.9300

P/E Ratio-4.35

Earnings Date08/12/2026

14.24M

Assets

149%

3Y-34.0%

5Y+213.0%

10Y+988.0%

28.47M

Total Liabilities

12%

3Y+30.0%

5Y-51.0%

10Y-24.0%

-14.23M

Total Equity

-27%

3Y+3445.0%

5Y-74.0%

10Y-61.0%

MiNK Therapeutics, Inc. Funding & Solvency Profile

INKT · NASDAQ

Current Assets

Cash & Cash Equivalents13.36B

Net Receivables0.00

Inventory0.00

Other Current Assets-13.35B

Total Current Assets14 M

Non-Current Assets

Property, Plant & Equipment390.87K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets391 K

Total Assets

14.24M

Financial Health Analysis

Current Ratio

1.06x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Working Capital

817 K

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

97% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

MiNK Therapeutics, Inc. Balance Sheet

INKT • NASDAQ

MiNK Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	13.4B	4.6M	3.4M	19.6M	38.9M	2.7M	299K
Cash & Short-Term Investments	13.4B	4.6M	3.4M	19.6M	38.9M	2.7M	299K
Net Receivables	0.0	0.0	0.0	0.0	23K	254K	526K
Accounts Receivables	0.0	0.0	0.0	0.0	23K	0.0	0.0
Other Receivables	0.0	0.0	0.0	0.0	0.0	254K	526K
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	87.7K
Prepaids	0.0	246.6K	53.1K	298.7K	1.8K	492.1K	87.7K
Other Current Assets	-13.3B	164.2K	178K	470.3K	721.3K	120.6K	-82K
Total Current Assets	13.8M	5M	3.6M	20.4M	39.6M	3.6M	918.4K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	390.9K	732.9K	954K	1.1M	606.6K	458.4K	390.5K
Other Non-Current Assets	0.0	0.0	0.0	0.0	0.0	539K	0.0
Total Non-Current Assets	390.9K	732.9K	954K	1.1M	606.6K	997.4K	390.5K
Total Assets	14.2M	5.7M	4.6M	21.5M	40.2M	4.6M	1.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.4M	2.7M	3.9M	5.8M	8.9M	3.1M	2.5M
Accounts Payable	3.4M	2.7M	3.9M	5.8M	3M	3.1M	2.5M
Other Payables	0.0	0.0	0.0	0.0	5.9M	0.0	0.0
Accrued Expenses	0.0	718K	1.8M	1.7M	1.8M	240K	1.7M
Short Term Debt	5.2M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	191K
Other Current Liabilities	4.4M	3.5M	5.7M	5.2M	5.8M	10.8M	3.1M
Total Current Liabilities	13M	7M	11.4M	12.7M	16.5M	14.2M	7.4M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	4.9M	0.0	0.0	0.0	43.8M	26.8M
Other Non-Current Liabilities	15.4M	13.4M	11.2M	9.2M	0.0	383.1K	3.4M
Total Non-Current Liabilities	15.4M	18.3M	11.2M	9.2M	0.0	44.2M	30.2M
Total Liabilities	28.5M	25.3M	22.6M	21.9M	16.5M	58.4M	37.6M
SHAREHOLDERS' EQUITY
Common Stock	48.0	40.0	346.0	339.0	335.0	87.0	241.0
Additional Paid-In Capital	143.2M	125.2M	115.8M	110.8M	107.3M	383.9K	294.8K
Retained Earnings	-156.7M	-144.2M	-133.4M	-110.9M	-82.9M	-52.7M	-36.5M
Accumulated Other Comprehensive Income/Loss	-718.9K	-631.6K	-430.9K	-292.5K	-625.3K	-1.5M	-132.6K
Other Total Stockholders' Equity	0.0	0.0	0.0	900.0	0.0	0.0	155.0
Total Stockholders' Equity	-14.2M	-19.6M	-18.1M	-401.3K	23.8M	-53.9M	-36.3M
Total Equity	-14.2M	-19.6M	-18.1M	-401.3K	23.8M	-53.9M	-36.3M
SUMMARY
Total Liabilities & Equity	14.2M	5.7M	4.6M	21.5M	40.2M	4.6M	1.3M
Total Debt	5.2M	4.9M	0.0	0.0	0.0	43.8M	26.8M
Net Debt	-13.4B	347.6K	-3.4M	-19.6M	-38.9M	41.1M	26.5M
Shares Outstanding	4,521,276	4,521,276	4,521,276	4,521,276	4,521,276	4,521,276	4,521,276

SEC Filings

INKT - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 15, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 15, 2026	May 15, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 17, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 31, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 31, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 19, 2026	March 13, 2026	2026	View Filing
8-K 8-K 2025 N/A	January 02, 2026	December 29, 2025	2025	View Filing
S-3/A S-3/A (Amended) N/A	December 10, 2025	December 10, 2025		View Filing
8-K 8-K 2025 N/A	December 08, 2025	November 14, 2025	2025	View Filing

Showing 1 to 10 of 71 filings

Related Guides

Blog Categories

Continue your INKT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.